Bulletin of Experimental Biology and Medicine

, Volume 160, Issue 1, pp 84–87

Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2

  • D. A. Khochenkov
  • E. Sch. Solomko
  • N. M. Peretolchina
  • O. O. Ryabaya
  • E. V. Stepanova
Article

DOI: 10.1007/s10517-015-3104-5

Cite this article as:
Khochenkov, D.A., Solomko, E.S., Peretolchina, N.M. et al. Bull Exp Biol Med (2015) 160: 84. doi:10.1007/s10517-015-3104-5
  • 70 Downloads

Alofanib is a potential allosteric inhibitor of FGFR2 used in oncology. The inhibitor blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo. The results indicate that Alofanib can inhibit angiogenesis.

Key Words

alofanib allosteric inhibitor of FGFR2 tumor angiogenesis endothelial cells 

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • D. A. Khochenkov
    • 1
  • E. Sch. Solomko
    • 1
  • N. M. Peretolchina
    • 1
  • O. O. Ryabaya
    • 1
    • 2
  • E. V. Stepanova
    • 1
  1. 1.N. N. Blokhin Russian Cancer Research CenterMoscowRussia
  2. 2.N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian FederationMoscowRussia

Personalised recommendations